Centene shorts retreat as analysts lift targets

Centene heads into the final stretch of Q3 with its short base at a multi-month low, options traders nudging more cautious, and a broadly supportive analyst community — a setup that reflects genuine fundamental re-rating rather than speculative froth.

The most telling signal this week is how decisively bearish positioning has unwound. Short interest has dropped 22% over the past five sessions to just 2.2% of free float — roughly 10.8 million shares — compared to 15.4 million at the start of September. That's a rapid exit by any measure, and it's happening against a backdrop where borrow is trivially cheap at 0.45% and availability is essentially unlimited, with over 60 shares available to borrow for every one already shorted. There is no squeeze mechanics at work here; shorts are leaving because the thesis isn't working, not because they're being forced out. The ORTEX short score has drifted down to 31.6 from 34.3 a week ago, consistent with that retreat.

Options tell a slightly different story — one worth watching. The put/call ratio has climbed to 0.50, running nearly two standard deviations above its 20-day average of 0.44 and within reach of the year's high of 0.66. In absolute terms the PCR remains call-heavy, so this isn't a defensive posture; but the drift higher through September suggests some participants are adding downside protection ahead of the October 27 earnings print. The stock fell 3.5% on the day following Q2 results in late July. That pattern, combined with the PCR's recent drift, hints at a market bidding modestly for insurance without fully turning bearish.

The analyst community is broadly constructive and has been revising higher since April results dropped. After a Q2 print in late July that came in better than feared on Medicaid ratios, a cluster of firms — Barclays, Bernstein, and Baird among them — raised targets into the $66–$80 range. Argus lifted its rating to Buy with an $80 target on August 11. JP Morgan, maintaining Neutral, nonetheless moved its target to $67 from $60 in early August. The consensus mean target sits at $71.78 against a current price of $67.66, implying modest upside. The bull case rests on the Medicaid HBR improvement to 93.4% and premium rate cohorts running around 5.5%; bears point to the sharp decline in low-cost Silver marketplace positions — from 55% of the portfolio in 2025 to an expected 42% in 2026 — and ongoing regulatory risk around government pay exposure. At 13.4x trailing earnings and 11.0x EV/EBITDA, the valuation remains undemanding for a managed care name that ranks in the 91st percentile on EPS surprise and 95th on 90-day earnings momentum.

The ownership picture is stable and broadly supportive. BlackRock reported an 8.4% stake as of August, adding nearly 1.7 million shares in its latest filing. Wellington Management reported a 2.7% stake but with the largest single-period addition in the top-15 holder list — over 10 million shares — on its June 30 filing, though the lag in filing dates means the current position could differ. No 13D activists appear on the register; all major holders file under 13G passive-holder rules. On the insider side, the General Counsel Christopher Koster sold roughly $6.9 million in open-market shares across two transactions in August — both outside any declared 10b5-1 plan. These are not compensation mechanics, and the size is material relative to recent insider activity, though the significance scores assigned are low and Koster is not a C-suite executive.

The next focal point is the October 27 earnings release. The setup going into it features a stock up 5% on the week and essentially flat over the past month at $67.66, shorts at their lowest level since at least early August, and options traders just beginning to hedge. The key variables to track between now and then are how the 10/1 Medicaid rate cohort performs relative to the 5.5% composite rate guidance, and whether the commercial HBR — already sequentially weaker at 89.9% — continues to compress against expectations.